JP6789288B2 - Ｓａｐ枯渇剤としてのｄ−プロリン誘導体 - Google Patents

Ｓａｐ枯渇剤としてのｄ−プロリン誘導体 Download PDF

Info

Publication number
JP6789288B2
JP6789288B2 JP2018521655A JP2018521655A JP6789288B2 JP 6789288 B2 JP6789288 B2 JP 6789288B2 JP 2018521655 A JP2018521655 A JP 2018521655A JP 2018521655 A JP2018521655 A JP 2018521655A JP 6789288 B2 JP6789288 B2 JP 6789288B2
Authority
JP
Japan
Prior art keywords
sap
compound
formula
disease
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018521655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531967A5 (enExample
JP2018531967A (ja
Inventor
アレクシ、ドニ
オリビエ、ミルゲ
ジェローム、トゥム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2018531967A publication Critical patent/JP2018531967A/ja
Publication of JP2018531967A5 publication Critical patent/JP2018531967A5/ja
Application granted granted Critical
Publication of JP6789288B2 publication Critical patent/JP6789288B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018521655A 2015-10-27 2016-10-25 Ｓａｐ枯渇剤としてのｄ−プロリン誘導体 Expired - Fee Related JP6789288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518950.9 2015-10-27
GBGB1518950.9A GB201518950D0 (en) 2015-10-27 2015-10-27 Compound
PCT/EP2016/075632 WO2017072099A1 (en) 2015-10-27 2016-10-25 D-proline derivatives as sap depleting agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020182835A Division JP7053762B2 (ja) 2015-10-27 2020-10-30 Ｓａｐ枯渇剤としてのｄ－プロリン誘導体

Publications (3)

Publication Number Publication Date
JP2018531967A JP2018531967A (ja) 2018-11-01
JP2018531967A5 JP2018531967A5 (enExample) 2019-12-05
JP6789288B2 true JP6789288B2 (ja) 2020-11-25

Family

ID=55130261

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521655A Expired - Fee Related JP6789288B2 (ja) 2015-10-27 2016-10-25 Ｓａｐ枯渇剤としてのｄ−プロリン誘導体
JP2020182835A Expired - Fee Related JP7053762B2 (ja) 2015-10-27 2020-10-30 Ｓａｐ枯渇剤としてのｄ－プロリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020182835A Expired - Fee Related JP7053762B2 (ja) 2015-10-27 2020-10-30 Ｓａｐ枯渇剤としてのｄ－プロリン誘導体

Country Status (12)

Country Link
US (1) US10328052B2 (enExample)
EP (1) EP3368532B1 (enExample)
JP (2) JP6789288B2 (enExample)
KR (1) KR20180067559A (enExample)
CN (1) CN108368095B (enExample)
AU (1) AU2016345462A1 (enExample)
BR (1) BR112018008582A2 (enExample)
CA (1) CA3002710A1 (enExample)
ES (1) ES2781550T3 (enExample)
GB (1) GB201518950D0 (enExample)
RU (1) RU2018119120A (enExample)
WO (1) WO2017072099A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
ES2182203T3 (es) * 1997-10-31 2003-03-01 Hoffmann La Roche Derivados de d-prolina.
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) * 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound

Also Published As

Publication number Publication date
RU2018119120A (ru) 2019-11-28
EP3368532B1 (en) 2020-01-15
US10328052B2 (en) 2019-06-25
CA3002710A1 (en) 2017-05-04
KR20180067559A (ko) 2018-06-20
JP2018531967A (ja) 2018-11-01
CN108368095A (zh) 2018-08-03
GB201518950D0 (en) 2015-12-09
US20190060274A1 (en) 2019-02-28
JP7053762B2 (ja) 2022-04-12
JP2021035963A (ja) 2021-03-04
BR112018008582A2 (pt) 2018-10-30
ES2781550T3 (es) 2020-09-03
WO2017072099A1 (en) 2017-05-04
AU2016345462A1 (en) 2018-04-26
CN108368095B (zh) 2021-06-08
EP3368532A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
JP2020509004A (ja) Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
JP2010518083A (ja) ピペリジン誘導体
WO2003080633A1 (fr) Nouveau derive d'$g(a)-amino-n-(diaminophosphinyl)lactame
US9737505B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
MX2012009894A (es) Inhibidores dimericos de iap.
JP2025516359A (ja) テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤
CA2944211A1 (en) Compositions and methods for treating neurodegenerative diseases
US10597385B2 (en) Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
JP7053762B2 (ja) Ｓａｐ枯渇剤としてのｄ－プロリン誘導体
US20240208940A1 (en) Small-molecule inhibitors for beta-catenin/bcell lymphoma 9 protein-protein interaction
CA3235104A1 (en) O-glcnacase (oga) inhibitor combination therapy
CA3102458A1 (en) Oga inhibitor compounds
JP2021527668A (ja) Ｏｇａ阻害化合物
WO2026030341A1 (en) Zervimesine for treating neurodegenerative disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191025

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200929

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201102

R150 Certificate of patent or registration of utility model

Ref document number: 6789288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees